Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Accounts Payables (2016 - 2025)

Historic Accounts Payables for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $26.2 million.

  • UroGen Pharma's Accounts Payables rose 3295.91% to $26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.2 million, marking a year-over-year increase of 3295.91%. This contributed to the annual value of $27.4 million for FY2024, which is 6586.65% up from last year.
  • Latest data reveals that UroGen Pharma reported Accounts Payables of $26.2 million as of Q3 2025, which was up 3295.91% from $31.0 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Accounts Payables high stood at $31.0 million for Q2 2025, and its period low was $8.6 million during Q2 2022.
  • In the last 5 years, UroGen Pharma's Accounts Payables had a median value of $16.4 million in 2023 and averaged $17.1 million.
  • In the last 5 years, UroGen Pharma's Accounts Payables plummeted by 1638.95% in 2022 and then skyrocketed by 8969.58% in 2023.
  • Over the past 5 years, UroGen Pharma's Accounts Payables (Quarter) stood at $12.1 million in 2021, then grew by 2.32% to $12.4 million in 2022, then surged by 33.55% to $16.5 million in 2023, then skyrocketed by 65.87% to $27.4 million in 2024, then dropped by 4.59% to $26.2 million in 2025.
  • Its last three reported values are $26.2 million in Q3 2025, $31.0 million for Q2 2025, and $30.3 million during Q1 2025.